India’s first dedicated life science and healthcare fund of $250 million has become one of the core investment themes for the venture capital firm.

In 2007, Eight Roads Ventures began its India operation will be used to invest the fund in 15-20 companies over three to four years, Prem Pavoor, senior partner, head of India and healthcare media, reported.

• Stocks in Focus: SJVN, Tata Power, Afcons Infrastructure, and Others
• Stocks Under F&O Ban: Adani Enterprises, Aarti Industries, Indraprastha Gas, and Others 
• RBI Defends Currency Moves to Protect Economy
• Trump 2.0: Drilling, Climate Rollbacks, and Global Energy Concerns
• Nvidia’s AI Chip Demand Soars, But Slowing Sales Growth Worries Investors

“We are sub-segment agnostic, stage agnostic and investment size agnostic. We are happy to make small investments and even growth stage ones that will go up to $40 million,” he said.

The new fund will continue to follow its two-pronged strategy for investing in companies. First is the win-from-behind strategy that involves investment in segments established in healthcare which are largely pharmaceuticals and healthcare services. The second strategy is to invest in companies with an aim to build leaders in segments that are still nascent.

“Healthcare has always been a key focus for us at Eight Roads globally. About 40-45% of our investment has been in the healthcare sector, and the balance is in tech, consumer, fintech,” said Pavoor.

“The launch of this healthcare fund reflects our confidence in the evolution of the India market and our commitment to helping ambitious founders scale, “Daniel Auerbach, senior managing partner and head of global ventures at Eight Roads Ventures, said in a statement.